This Article Full Text (PDF) Other Versions of this Article: AAC.00550-07v1 51/11/4191    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bogdanovich, T. Articles by Appelbaum, P. C. Search for Related Content PubMed PubMed Citation Articles by Bogdanovich, T. Articles by Appelbaum, P. C.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.00550-07
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

ANTISTAPHYLOCOCCAL ACTIVITY OF CG400549, A NEW EXPERIMENTAL FabI INHIBITOR, COMPARED TO OTHER AGENTS

Department of Pathology, Hershey Medical Center, Hershey, PA 17033

^* To whom correspondence should be addressed. Email: pappelbaum{at}psu.edu.

	Abstract

Amongst 203 strains of Staphylococcus aureus, MICs for CG400549 were 0.06-1.0 µg/ml, with MIC₅₀ and MIC₉₀ values each of 0.25 µg/ml. All strains were susceptible to linezolid and quinupristin-dalfopristin (MICs 0.25-2.0 µg/ml). Daptomycin MICs were 0.25-2.0 µg/ml for methicillin-susceptible and 0.25-4.0 µg/ml against methicillin-resistant strains (including vancomycin-intermedaite strains). Single-passage selections showed low resistance frequencies of CG400549 but multistep analysis showed that CG400549 yielded resistant mutants after 14-17 days in all strains tested.